NCT02362438View on ClinicalTrials.gov

Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 24, 2015

Primary Completion Date

June 30, 2030

Study Completion Date

April 1, 2035

Conditions
Giant Axonal NeuropathyGene Transfer
Interventions
GENETIC

scAAv9/JeT-GAN

scAAV9/JeT-GAN is a biological gene transfer reagent

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH